Proteasomal inhibition as a treatment strategy for Parkinson's disease: The impact of α-synuclein on Nurr1

Journal of Neuroscience

Volumn 32, Issue 46, 2012, Pages 16071-16073

  Devine, Michael J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; NUCLEAR RECEPTOR RELATED FACTOR 1; PROTEASOME; UBIQUITIN;

ARTICLE; AUTOPHAGY; CELL SURVIVAL; ENZYME INHIBITION; FEEDBACK SYSTEM; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 84869065872     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4224-12.2012     Document Type: Article

References (10)

1. Bedford L, Hay D, Devoy A, Paine S, Powe DG, Seth R, Gray T, Topham I, Fone K, Rezvani N, Mee M, Soane T, Layfield R, Sheppard PW, Ebendal T, Usoskin D, Lowe J, Mayer RJ (2008) Depletion of 26S proteasomes in mouse brain inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration. J Neurosci 28:8189-8198.
2. Butts BD, Hudson HR, Linseman DA, Le SS, Ryan KR, Bouchard RJ, Heidenreich KA (2005) Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via differential regulation of pro-survival and pro-apoptotic transcription factors. Mol Cell Neurosci 30:279-289.
3. Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH (2006) Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 494:495-514.
4. Cook C, Stetler C, Petrucelli L (2012) Disruption of protein quality control in Parkinson's disease. Cold Spring Harb Perspect Med 2:a009423.
5. Hardy J (2010) Genetic analysis of pathways to Parkinson disease. Neuron 68:201-206.
6. Kadkhodaei B, Ito T, Joodmardi E, Mattsson B, Rouillard C, Carta M, Muramatsu S, Sumi-Ichinose C, Nomura T, Metzger D, Chambon P, Lindqvist E, Larsson NG, Olson L, Björklund A, Ichinose H, Perlmann T (2009) Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci 29:15923-15932.
7. Lin KI, Baraban JM, Ratan RR (1998) Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration. Cell Death Differ 5:577-583.
8. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H (2009) Leucinerich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson'sdisease- related mutant α-synuclein. Neuron 64:807-827.
9. Lin X, Parisiadou L, Sgobio C, Liu G, Yu J, Sun L, Shim H, Gu XL, Luo J, Long CX, Ding J, Mateo Y, Sullivan PH, Wu LG, Goldstein DS, Lovinger D, Cai H (2012) Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci 32:9248-9264.
10. Yang YX, Latchman DS (2008) Nurr1 transcriptionally regulates the expression of alphasynuclein. Neuroreport 19:867-871.